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Acute administration of the primary psychoactive constituent of cannabis, Δ-9-tetrahydrocannabinol
(THC), impairs human facial affect recognition, implicating the endocannabinoid system in emotional
processing. Another main constituent of cannabis, cannabidiol (CBD), has seemingly opposite
functional effects on the brain. This study aimed to determine the effects of THC and CBD, both
alone and in combination on emotional facial affect recognition. 48 volunteers, selected for high and
low frequency of cannabis use and schizotypy, were administered, THC (8 mg), CBD (16 mg), THC
+CBD (8 mg+16 mg) and placebo, by inhalation, in a 4-way, double-blind, placebo-controlled
crossover design. They completed an emotional facial affect recognition task including fearful, angry,
happy, sad, surprise and disgust faces varying in intensity from 20% to 100%. A visual analogue scale
(VAS) of feeling ‘stoned’ was also completed. In comparison to placebo, CBD improved emotional
facial affect recognition at 60% emotional intensity; THC was detrimental to the recognition of
ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment. Relative to
placebo, both THC alone and combined THC+CBD equally increased feelings of being ‘stoned’. CBD
did not inﬂuence feelings of ‘stoned’. No effects of frequency of use or schizotypy were found. In
conclusion, CBD improves recognition of emotional facial affect and attenuates the impairment
induced by THC. This is the ﬁrst human study examining the effects of different cannabinoids ono.2014.11.014
hed by Elsevier B.V. This is an open access article under the CC BY license
/by/4.0/).
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C. Hindocha et al.326emotional processing. It provides preliminary evidence that different pharmacological agents acting
upon the endocannabinoid system can both improve and impair recognition of emotional faces.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Decoding basic human emotional expressions is a key adaptive
skill that allows for the prediction of future behaviour and is
essential for social communication, interpersonal relationships
and mental health (Carton et al., 1999). Impairments in the
perception of emotional expression have been reported in
depression, anxiety, schizophrenia (Phillips et al., 2003) and in
users of a number of drugs (Goldstein and Volkow, 2011)
including cannabis (Platt et al., 2010; Hindocha et al., 2014).
Acutely, cannabis and its main active ingredient, Δ-9-
tetrahydrocannabinol (THC) produce euphoria and cognitive
impairments (Curran et al., 2002; Fernández-Serrano et al.,
2011) alongside transient negative emotional states such as
anxiety and paranoia (D'Souza et al., 2004). These emotion-
based changes suggest the endocannabinoid system is involved
with emotional processing. Cannabinoid receptors are important
in processing emotional material (Marsicano et al., 2002) and are
abundant in limbic regions including the amygdala, cingulate
cortex and hippocampus, as well as the frontal cortex (Pamplona
and Takahashi, 2012). Cannabis consists of over 100 cannabi-
noids, the two most abundant being THC, a partial agonist at the
CB1 receptor (Pertwee, 2008) and cannabidiol (CBD) which has a
complex mode of action involving several receptor, re-uptake
and enzymatic proteins. It also inhibits the reuptake and
hydrolysis of the endocannabinoid, anandamide (Pertwee,
2008). These cannabinoids have opposing psychological and
emotional properties, for example, whilst THC can induce acute
anxiety (Martin-Santos et al., 2012) and amnesic effects (Curran
et al., 2002), CBD may have some anxiolytic effects (Guimaraes
et al., 1990) and has been shown to block THC-induced memory
impairments (Morgan et al., 2010b; Englund et al., 2013).
In experienced cannabis users, THC impairs the recognition
of unambiguous (100% emotional intensity) faces displaying
fear and anger in a dose-dependent manner (Ballard et al.,
2012) and impairs accuracy scores for negative emotional
faces only (Bossong et al., 2013). Three functional neuroima-
ging studies have investigated the involvement of the endo-
cannabinoid system in human emotional processing with mixed
results. Acute THC administration (7.5 mg oral) has been
shown to decrease amygdala BOLD (blood-oxygen level depen-
dent) response to threatening faces (Phan et al., 2008). Using
the same emotional face discrimination task, Bossong et al.
(2013) found 8 mg pulmonary THC decreased activity in a
network including the amygdala, hippocampus, parietal and
prefrontal gyrus in response to threatening faces; however
activity in this network increased during non-threatening
faces. Fusar-Poli et al. (2009) conducted a gender discrimina-
tion task with negative faces and found THC (10 mg oral)
increased activity in the precuneus and primary motor cortex
and decreased activity in the right inferior frontal gyrus,
superior temporal gyrus and left medial frontal gyrus.
CBD has rarely been studied in the context of emotional
processing and has not yet been shown to have behavioural
effects. Nevertheless, CBD has been hypothesised to reduce
anxiety through an anterior cingulate cortex (ACC) mediatedattenuation of the amygdala, in response to fearful and angry
faces (Fusar-Poli et al., 2009; Kowal et al., 2013). In support of
this, CBD disrupts the effective connectivity between ACC and
amygdala (Fusar-Poli et al., 2010) and produces opposite effects
to THC, on amygdala BOLD activation and skin conductance
response (SCR) ﬂuctuations when viewing fearful faces
(Bhattacharyya et al., 2010). The opposing effects of THC and
CBD on BOLD signal and SCRs during this emotional processing
task suggest whilst THC may impair emotional recognition, CBD
may tentatively be expected to improve it, relative to placebo.
Very little is known about how THC and CBD interact. Alt-
hough THC and CBD are the most abundant cannabinoids found
in the cannabis plant, high THC varieties are most common.
Nevertheless, the ratio of CBD:THC varies hugely (e.g. 0.0–4.3;
Freeman et al., 2014). In smoked cannabis, THC and CBD are
typically both present, high levels of CBD appear to protect
against some psychotomimetic, anxiogenic, cognitive impairing,
and dependence forming effects of THC (Morgan and Curran,
2008; Morgan et al., 2010a, 2010b, 2012). We therefore
hypothesised acute THC would impair facial affect recognition,
CBD alone might enhance it and in combination, CBD might
protect against THC-induced impairments.
The acute effects of cannabis also depend on individual
vulnerabilities to its harmful effects. Habitual cannabis use is
associated with impairments in emotional processing; heavy
users show impaired accuracy when non-intoxicated (Platt
et al., 2010; Hindocha et al., 2014). Simultaneously, heavy can-
nabis users show tolerance to cognitive impairment following
acute THC administration (D'Souza et al., 2008). Evidence for the
association between adolescents using cannabis and psychosis
continues to accumulate. Longitudinal population-based studies
show a two-fold increase in risk of psychotic illness (Moore et al.,
2007; Di Forti et al., 2007). Schizotypy or ‘psychosis-proneness’
has further been associated with deﬁcits in emotional processing
(Germaine and Hooker, 2011; Edwards et al., 2001) and
enhanced acute response to cannabis (Mason et al., 2009). This
study aimed to determine the effects of THC and CBD, both
alone and in combination on emotional facial affect recognition.
However, given the signiﬁcant inter-relationship between emo-
tional recognition, psychosis-proneness and cannabis use, we
aimed to explore how variations in frequency of use and
schizotypy might modulate an individual's acute response to
cannabinoids. Therefore we recruited 48 cannabis users, half of
whom used the drug heavily and half used it recreationally. In
each of these two groups, half the participants scored high in
schizotypy and half low in schizotypy. All 48 participants were
tested on 4 separate days; each being administered a single dose
of inhaled THC, CBD, combined THC+CBD and placebo.
2. Experimental procedures
2.1. Participants
Participants were recruited as 24 light (1–24 days per month) and 24
heavy (25+ days per month) cannabis users following the criteria of
Morgan et al. (2012). 50% of each of these groups scored high, and 50%
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and were selected from the bottom and top quartiles of our previous
study large-scale study of over 400 cannabis users (Morgan et al., 2012).
They were recruited as such to systematically investigate the effects of
schizotypy and tolerance on the interaction between the endogenous
cannabinoid system and emotional processing. However, in the 6 months
to 2 years between testing on the two experiments, some participants
changed their level of cannabis use and schizotypy scores (reported in
Table 1). Participants were matched for age and premorbid verbal
intelligence (as measures by the spot the word task) across heavy and
light users. Inclusion criteria were: (i) self-reported abstinence from
cannabis, other drug and alcohol use for 24 h prior to each test day; (ii)
ﬂuent in English, (iii) normal or corrected to normal vision. Exclusion
criteria were: current self-reported (i) respiratory health problems or
physical health problems, (ii) pregnancy or the risk of being pregnant,
(iii) clinically diagnosed learning impairments, (iv) clinically diagnosed
schizophrenia/psychosis or substance abuse problems, and (v) illicit
drug use other than cannabis more than once a week.2.2. Design
A randomised, double-blind, placebo controlled study was used to
compare the acute effects of inhaled THC (8 mg), CBD (16 mg) and their
combination (8 mg THC+16 mg CBD) with placebo (ethanol vehicle).
Cannabinoids were formulated in alcohol solution and were purchased
from STI Pharmaceuticals (Brentwood, Essex, UK). Four groups of
individuals took part in this balanced crossover design: group (low
schizotypy, light cannabis users (LS-L); low schizotypy, heavy users (LS-
H); high schizotypy, light users (HS-L); high schizotypy, heavy users (HS-
H)). N=12 per experimental group was chosen to detect THC-induced
(compared to placebo) impairment in memory at a power of 0.83
(Curran et al., 2002). Order of drug administration was randomised
using a partial Latin square, resulting in 12 different combinations.Table 1 Group demographics (means and SD) and questionnai
Light
Low schizotypy
Age 21.00 (2.13)
Gender ratio (m:f) 9:3
Education (years) 15.75 (1.22)
BDI-11n 3.25 (3.92)
SPQ 9.25 (12.66)
STAI 35.67 (10.29)
Personal diagnosis of mental health problems 0
Familial diagnosis of mental health problems 1 Bipolar
Familial diagnosis of substance use problems 0
Spot the word task 51.17 (5.13)
Cannabis (N) 12
Cannabis used (years) 5.88 (3.48)
Cannabis use (days/month) 11.92 (6.84)
Days since last use 2.50 (1.38)
Time to smoke 3.5 g (days) 11.50 (15.83)
Alcohol (N) 12
Alcohol used (years) 6.04 (2.18)
Alcohol (days/month) 11.54 (5.66)
Tobacco (N) 6
Tobacco used (years) 4.57 (1.90)
Tobacco (days/month) 20.00 (11.40)
Tobacco cigarettes (day) 6.66 (3.77)
n1 Person's BDI is missing and 1 person has been replaced with theParticipants had all previously partaken in a naturalistic study of
cannabis in 400 young people and had consented to be contacted
about subsequent studies. Participants were screened for eligibility via
a brief telephone call. Testing sessions occurred on four occasions each
separated by a one week wash-out to minimise carry-over effects (43
times elimination half-life of THC; D'Souza et al., 2008). Participants
completed baseline questionnaires before, and then commencing
10 min after drug administration. Four versions of the emotional
processing task were administered. Version was counterbalanced. The
test battery took approximately 1.5 h on each test day and included
other tasks not reported. Participants were reimbursed £120 for their
time on the last day and debriefed fully. All participants provided
written, informed consent on each occasion. Ethical approval was given
by the UCL Graduate School Ethics Committee.2.3. Assessments
2.3.1. Emotional processing task
This computer based task assessed emotional facial affect recogni-
tion and is described in more detail in Hindocha et al. (2014). Faces
were taken from the NimStim Face Stimulus Set (Tottenham et al.,
2009) and were created with Fotomorph 5.2. Two male and two
female faces were used to portray the 6 basic emotions – happiness,
sadness, anger, disgust, fearful, surprise and neutrality. Each face
varied in the degree of intensity it portrayed from 0% (neutral) to
100% on a continuum in 10% increments. Approximately 200 fucidial
markers were positioned on the actors' neutral face around main
facial features. The markers were then placed onto the actor's
emotional expression and morphed between the full emotion (100%)
and neutral (0%) in 10% increments and stills were taken at these
points (Harmer et al., 2003). These were combined into 20%
increments to give 5 levels of intensity of 20%, 40%, 60%, 80% and
100% for each emotion. In total, 250 stimuli were shown, 40 faces/re data based on recruitment strategy.
Heavy
High schizotypy Low schizotypy High schizotypy
22.90 (2.02) 21.42 (1.62) 21.50 (1.38)
7:5 11:1 7:5
15.79 (1.30) 15.04 (1.77) 14.50 (2.31)
7.67 (7.10) 2.75 (1.81) 15.75 (12.95)
22.83 (11.84) 10.58 (7.07) 22.80 (17.07)
41.67 (8.19) 33.00 (6.63) 42.58 (10.25)
0 0 2 Depression, 1 ADHD
0 1 Depression 1 Depression
1 Alcohol 1 Crack, 1 Other 2 Alcohol
49.75 (4.37) 51.42 (4.89) 48.75 (4.94)
12 12 12
6.91 (3.00) 5.92 (2.15) 5.33 (2.39)
11.71 (10.24) 24.38 (9.06) 26.00 (5.64)
13.83 (33.64) 4.66 (8.15) 1.92 (0.79)
20.54 (16.13) 7.52 (8.84) 3.92 (2.75)
12 12 12
6.71 (2.66) 6.50 (2.19) 5.25 ( 7.85)
8.04 (4.87) 10.00 (7.67) 11.12 (7.43)
9 10 9
5.22 (2.54) 5.50 (2.37) 5.83 (3.02)
22.45 (12.16) 23.80 (10.89) 27.56 (7.33)
6.39 (3.12) 8.55 (5.31) 9.22 (4.47)
mean.
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come variable was recognition accuracy calculated as percentage of
correctly identiﬁed emotions.
All stimuli were presented in the centre of a white background.
Participants indicated the correct facial expression as quickly and
as accurately as possible with no feedback except on the 7 practice
trials at the beginning of the task. Following the offset of a black
ﬁxation cross (250 ms) participants were presented with a single
face for 500 ms and then pressed a labelled key (response)
corresponding to an emotion (see Figure 1f). Their response led
to the next stimulus onset. All responses were self-paced. Trials
were randomised apart from the restriction that two faces of one
emotion were not shown more than twice in succession.2.3.2. Questionnaire measures
Before drug administration participants completed the Beck
Depression Inventory (BDI; Beck et al., 1961), the trait scale of
the Spielberger State Trait Anxiety Inventory (STAI; Spielberger
et al., 1983), the Schizotypal Proneness Questionnaire (SPQ; Raine,
1991) and the Spot the Word Test – which correlates highly with
premorbid verbal intelligence (STWT; Baddeley et al., 1993).
Additionally, participants completed 10-point VAS scales of sub-
jective effects of ‘stoned’, anchored at ‘not stoned’ and ‘extremely
stoned’, VAS ‘anxiety’ anchored at ‘no anxiety’ and ‘very severe
anxiety’, VAS ‘alert’ anchored at ‘not alert’ and ‘extremely alert’,
VAS ‘happy’, anchored at ‘sad’ and ‘happy’ at pre-drug adminis-
tration (15 min), 2 min after drug administration (+2 min), and
then every 30 min (+30 min, +60 min, +90 min and +120 min).2.3.3. Drug administration
Cannabinoids and placebo (ethanol vehicle) were administered using
a Volcano Medic Vaporisor (Storz and Bickel, Tuttlingen, Germany); a
safe, effective and replicable method of intrapulmonary cannabinoid
administration (Hazekamp et al., 2006; Abrams et al., 2007). This
administration method was preferred as it overcomes the variable
bioavailability of oral administration and bypasses inhalation of toxic
compounds as per burning cannabis (Van Hell et al., 2011). Moreover,
ﬁnal pulmonary, plasma and subjective levels are equivalent to
smoked cannabis (Hazekamp et al., 2006; Abrams et al., 2007).
Cannabinoid doses were selected on the basis of prior research in
which 8 mg THC was vaporised into a single balloon using a VolcanoFigure 1 Percentage accuracy for each intensity, over all emo
drug intensity interaction. (a) Percentage accuracy at 20%, (b) sign
contrast between CBD and Placebo at 60%, (d) percentage accurac
single trial in the emotional processing task. Error bars represent sdevice (Bossong et al., 2009). In a sample of incidental cannabis
users, this dose elicited robust psychotomimetic and subjective
effects, and produced a reduction of [11C] raclopride binding in the
ventral stritum, consistent with an increase of dopamine (Bossong
et al., 2009). This dose was further based on the pharmacokinetic/
pharmacodynamic proﬁle of inhaled THC (Zuurman et al., 2008). We
have previously reported psychophysiological and behavioural effects
following 32 mg CBD (Das et al., 2013). In this study a dose of 16 mg
was chosen to create a CBD:THC ratio of 2:1, reﬂecting the upper
limit (mean +3 SD) found in high CBD/low THC cannabis preparations
(Freeman et al.,2014). 54% (78%) of the loaded dose is delivered in
the administration balloon (Hazekamp et al., 2006), thus the aim was
to deliver the maximum total amount of cannabinoids vaporised such
that 5 mg THC and 10 mg CBD would be inhaled. Participants were
given a practise balloon to familiarise themselves with the procedure
before any drug administration occurred. On drug days, 8 mg THC
and/or 16 mg CBD dissolved in ethanol were administered on a 10-s
inhalation cycle wherein the participant was instructed to ﬁrst fully
exhale, next fully inhale from the balloon, hold their breath for 10 s
and then fully exhale; this was repeated until the balloon was empty
(Bossong et al., 2009). A single balloon was ﬁlled (as per guidelines
from Hazekamp (2009)), covered with an opaque bag, and adminis-
tered by an independent researcher to maintain blinding of the
experimenter collecting behavioural data and participant.2.4. Statistical analyses
Between group analyses were conducted in the groups that participants
were recruited as. Demographics and scores on questionnaires were
analysed using ANOVAs with two between-subjects variables (frequency
of use, schizotypy). When variables showed a main effect or interaction
this was explored with post-hoc tests (Bonferroni-corrected). For the
emotional processing task, a mixed model repeated measures ANOVA
was carried out on mean percentage accuracy. This included within
subjects-factors of drug (placebo, THC, THC+CBD, CBD), emotion
(angry, disgust, fear, happy, sad, surprise) and intensity (20%, 40%,
60%, 80%, 100%) and two between subjects factors (frequency of use –
light/heavy; schizotypy – high/low). Simple effects analyses of each
drug condition in comparison to placebo were used to explore drug main
effects and interactions (Bonferroni corrected). Other interactions were
explored with separate ANOVAs and Bonferroni-corrected t-tests. Onetions and single trial design. Asterisks indicate a signiﬁcant
iﬁcant contrast between THC and Placebo at 40%, (c) signiﬁcant
y at 80%, (e) percentage accuracy at 100%, and (f) design of a
tandard error of the mean (7SEM).
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Figure 2 (a) Recognition of all emotions over the different
intensities. Asterisks' illustrate a signiﬁcant drug by intensity
interaction where at 40%, we found a signiﬁcant contrast between
placebo and THC; at 60%, a signiﬁcant contrast between placebo
and CBD and at 100%, no signiﬁcant contrast after correction for
multiple comparisons.
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processing task only for being 43 standard deviations away from the
mean in450% of trials. This participant remains in all analyses that do
not involve emotional processing data. Further exploration included
between-group differences in gender and of carry-over effects. Gender
was included as a between-subjects factor in the ANOVA as it has
previously been shown that males show a lower accuracy on this task
(Hindocha et al., 2014). Carry-over effects were explored with mixed
model ANOVAs conducted separately for each drug, including the within
subjects factor of intensity (20%, 40%, 60%, 80%, 100%) an additional
between subjects factor of ‘occasion’ (1, 2, 3, 4). Schizotypy and
frequency of use were not entered into these models in order to
minimise the number of factors in this exploratory analysis.
Cannabinoid effects on VAS ‘stoned’, VAS ‘anxiety’, VAS ‘alert’,
and VAS ‘happy’ were analysed using a repeated measures ANOVA
with Drug (Placebo, THC, THC+CBD, CBD) and Time (15, +2, +30,
+60, +90, +120) as within-subjects' factors and between-subject'
factors of frequency of use and schizotypy. Interactions were
followed up with separate Bonferroni corrected ANOVAs and pairwise
comparisons as necessary (p=0.008). Greenhouse Geisser corrections
(degrees of freedom rounded to the nearest integer) were used when
assumptions of sphericity were violated for all analyses.
3. Results
3.1. Demographics (Table 1)
Groups did not differ in age (F(3,44)=2.54, p=0.070), gender,
scores on the spot the word task (F(3,44)=0.80, p=0.490), last
use of cannabis, or number of year’s cannabis had been used
(F(3,44)=0.67, p=0.580). There was a main effect of schizo-
typy on scores on the SPQ (F(1,44)=12.47, po0.001), BDI
(F(1,43)=14.70, po0.001) and STAI (F(1,44)=9.05, p=0.004)
where the high schizotypy group had higher scores than the
low schizotypy group for each measure. Light and heavy users
of cannabis differed on the time to smoke 3.5 g of cannabis
(F(1,46)=8.22, p=0.006) and on number of days per month
they used cannabis (F(1,44)=8.54, p=0.005) where heavy
users smoked 3.5 g in less days and used cannabis on more
days per month than light users.
3.2. Emotional processing task
Repeated measures ANOVA revealed a drug intensity interac-
tion (F(8,355)=3.25, p=0.001) and an emotion schizotypy
interaction (F(4,170)=3.02, p=0.020). In exploring the drug
intensity interaction we conducted repeated measures ANOVAs
collapsing over emotion to compare each drug over different
intensities as seen in Figure 1 (20–100%). Figure 2 depicts the
increase in performance with increasing intensity. At 40% we
found a main effect of drug (F(3,138)=7.56, po0.001). Simple
contrasts showed a signiﬁcant difference only between THC and
placebo (F(1,46)=16.20, po0.001) with poorer accuracy after
THC (Figure 1b); no other contrasts were signiﬁcant. To test the
hypothesis that THC+CBD would protect against the negative
effects of THC here, we conducted a paired-samples t-test
between THC and THC+CBD at 40% which revealed that
participants were more accurate on THC+CBD (M=43.52%,
SD=10.9%) compared to THC alone (M=39.75%, SD=4.51%)
(t(46)=2.33, p=0.024). We also found a main effect of drug at
60% (F(3,138)=7.56, p=0.004). The signiﬁcant contrast here was
CBD vs. placebo (Figure 1c); Participants were signiﬁcantly
more accurate after CBD (F(1,46)=7.32, p=0.010). The effectsize for this contrast (partial eta squared=0.137) which is
within the moderate range of 0.10–0.30. Finally, at 100%, we
found a main effect of drug (F(3,138)=6.95, po0.001) but no
contrasts was signiﬁcant after correcting for multiple compar-
isons. No drug differences were found at 20% or 80%.
There were also main effects of drug (F(3,129)=4.80,
p=0.003), emotion (F(4,170)=61.86, po0.001) and intensity
(F(2,104)=2540.89, po0.001). There were no main effects of
frequency of use or schizotypy or any other interactions.
Simple contrasts revealed that the main effect of drug was
reﬂecting signiﬁcantly greater accuracy following CBD com-
pared to placebo (F(1,43)=5.30, p=0.026). Equivalent con-
trasts for THC and THC+CBD vs. placebo were not
signiﬁcant.
The emotion schizotypy interaction was explored with
independent t-tests, collapsing over intensity and drug.
After correction for multiple comparisons there were no
signiﬁcant differences between high and low schizotypy
groups for any emotion. However, the direction of this
interaction suggests the high schizotypy group (M=25.93%,
SD: 9.89%) were less accurate than the low schizotypy group
(M=32.15%, SD=9.18%) for fearful faces only.
3.3. Exploratory analyses
3.3.1. Gender
There were no main effects or interactions with gender;
moreover, this analysis did not alter the main effects or
interactions above.
3.3.2. Carry-over effects
Due to the small cell sizes and large number of orders (12 in
total), order could not be included as a between-subjects
factor. For placebo, THC or CBD, occasion did not interact
C. Hindocha et al.330with accuracy. For the THC+CBD condition, an occa-
sion accuracy interaction was detected (F(9, 120)=1.99,
p=0.044). When Bonferroni corrected, this was no longer
signiﬁcant, however for due diligence, we then coded
whether the THC+CBD day was preceded by placebo (or
was on the ﬁrst day), THC or CBD. No interaction was found
between performance on the THC+CBD day and the drug
occasion it was preceded by.
3.4. VAS ‘stoned’ (Figure 3)
Repeated measures ANOVA revealed a drug time interac-
tion for feelings of ‘stoned’ (F(8,330)=9.25, po0.001) as well
as a main effect of drug (F(3,114)=15.60, po0.001) and time
(F(2,100)=72.96, po0.001). There was no signiﬁcant
between-subjects' main effects or interactions with drug
or time. To explore this interaction we conducted ANOVAs
for each time-point and found drug main effects at all time-
points post drug administration (all p'sr0.001). At all time
points post drug administration, Bonferonni-corrected
paired t-tests between drug conditions at each time
revealed greater ‘stoned’ feelings for THC vs. placebo (all
p'sr0.001) and greater feelings for stoned for THC+CBD
vs. Placebo (all p'sr0.001). Feelings of ‘stoned’ between
CBD and placebo did not differ at any time (all p's40.05).
We found greater feelings of ‘stoned’ for THC compared to
CBD at +30, +60, +90 and +120 min (all p'so0.001) and
greater feelings of ‘stoned’ were also found for THC+CBD in
comparison to CBD alone at these time points (all
p'so0.001). Finally, THC and THC+CBD produced equiva-
lent ratings of ‘stoned’ across all time points (all p's40.05).
3.5. VAS ‘anxiety’, VAS ‘alert’ and VAS ‘happy’
Comparable repeated measures ANOVAs were conducted for
the remaining VAS scales. VAS ‘anxiety’ revealed a main
effect of drug (F(2,95)=3.05, p=0.050), and a main effect of
time (F(3,129)=2.96, p=0.030). After correction for multipleFigure 3 Subjective ratings of feeling ‘stoned’ averaged across all
cannabinoid conditions are indicated as followed: nnnTHC vs. place
(Po0.001); THC+CBD vs. CBD (po0.001). Error bars representcomparisons, there was no signiﬁcant difference between
drug conditions. No interaction between drug and time
emerged and there was no signiﬁcant between-subjects'
main effects or interactions with drug or time. For VAS
‘alert’, the repeated measures ANOVA did not reveal any
main effects or interactions apart from a main effect of
time (F(5,210)=22.17, po0.001), for VAS ‘happy’, no main
effects or interaction emerged.3.6. Correlations
Correlations were carried out between self-report measures
(BDI, STAI, SPQ and STWT) with performance on the emo-
tional processing task across cannabinoid administration, to
investigate whether baseline psychological wellbeing was
associated with performance accuracy, however no correla-
tions emerged (all p's40.05). Moreover, accuracy at 60%
between CBD and placebo, and at 40% between THC and
placebo did not correlate with SPQ scores or frequency of
cannabis use. No correlations emerged between self-
reported measures and accuracy on individual emotions
collapsed over drug. VAS ‘stoned’, ‘anxiety’, ‘alert’ and
‘happy’ at all time-points did not correlate with accuracy on
the emotional processing task or self-reported measures.4. Discussion
This study aimed to investigate the separate and combined
effects of THC and CBD on emotional facial affect recognition.
This is the ﬁrst human study to examine the effects of a
combination of cannabinoids on emotional processing. We ﬁrst
hypothesised THC would be detrimental to emotional proces-
sing (Ballard et al., 2012; Bossong et al., 2013). Second, we
hypothesised when CBD was combined with THC, it would
protect against the impairments produced by THC (Morgan and
Curran, 2008; Morgan et al., 2010a, 2010b, 2012). We found
acute administration of cannabinoids altered facial affectparticipants for all time points. Signiﬁcant differences between
bo (pr0.001); ♯♯♯THC+ vs. placebo (pr0.001); †††THC vs. CBD
standard error mean (7SEM).
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face portrayed, irrespective of emotion. Our most novel
ﬁnding is in comparison to placebo, acute administration of
CBD improves emotional facial affect recognition, at 60%
intensity of emotion. THC, in comparison to placebo, signiﬁ-
cantly impaired the recognition of emotional faces of 40%
intensity. Moreover, in tentative support of our hypothesis, the
combination of THC with CBD protected against the impair-
ment THC alone produced at 40%. These subtle ﬁndings
suggest cannabinoids inﬂuence emotional processing at levels
of intermediate emotional intensity (above and below 50%),
and further these effects persist after a conservative correc-
tion for multiple comparisons. Above 60%, all participants
reach ceiling responses of accuracy.
CBD has known anxiolytic and antipsychotic properties. It
has previously been hypothesised CBD exerts its anxiolytic
effect through an ACC-mediated attenuation of the amygdala
in response to threat-related faces (Fusar-Poli et al., 2009;
Kowal et al., 2013). This study provides the ﬁrst evidence
that a single dose of inhaled CBD can produce a behavioural
improvement in emotional facial recognition. Furthermore,
this was equal across groups of high and low schizotypy and
frequency of use. Although only evident at 60% emotional
intensity, this suggests, if used clinically, CBD would be
equally effective in groups of high and low schizotypy and
frequency of cannabis use. This is unlikely to be a product of
the change in subjective effects as we found no difference
between CBD and placebo on feelings of VAS scales of
‘stoned’, ‘anxiety’, ‘alert’ or ‘happy’. Ratings of ‘stoned’
were not inﬂuenced by frequency of use, replicating ﬁndings
that frequent users cannot be distinguished from healthy
controls by euphoric effects (D'Souza et al., 2008). It should
be noted that although the light users reported here were
using cannabis at a recreational level (12 days per month),
this was higher than controls in D'Souza et al. (2008) (0.16
exposures in the last month) and may still be associated with
tolerance. Feelings of ‘stoned’ did not interact with schizo-
typy, consistent with D'Souza et al. (2005), who did not ﬁnd
an interaction between euphoric effects of THC and time, in
patients with schizophrenia and further consistent with
Barkus et al. (2006) who found that the pleasurable effects
of cannabis, as measured by the Cannabis Experiences
Questionnaire, were not associated with schizotypy.
In experienced cannabis users, Ballard et al. (2012)
previously found that 7.5 and 15 mg oral THC impaired
recognition of negative faces (100% intensity), in a dose
dependent manner in healthy volunteers. Bossong et al.
(2013) found that 8 mg inhaled THC reduced accuracy of
recognising negative emotional faces. In the present study
however, 8 mg inhaled THC consistently decreased accuracy
across all emotions but only at 40% emotional intensity. The
disparity between these studies may possibly be a result of
the sample characteristics, as previous studies have used
incidental cannabis users. The reduced ability to interpret
ambiguous emotional faces after THC inhalation might
increase social risk-taking behaviour and in affective dis-
orders the skewed interpretation of ambiguity can be seen as
a causal mechanism in the maintenance of the disorder. In
major depression, for example, research clearly shows a
reduced recognition to both positive and negative emotional
valence which suggests that both recognition accuracy and
interpretation of ambiguous faces are important in theaetiology of the disorder (Bourke et al., 2010). Our previous
ﬁndings with heavy cannabis users, using the same paradigm,
show signiﬁcant non-acute impairments at 40%, 60% and 100%
(Hindocha et al., 2014). Thus perhaps, when uncertainty is
high, THC seems to impair performance. Cannabis users
require more information from a face to discern an emotion
(Platt et al., 2010). Therefore, perhaps when the available
information is low in cannabis users, THC further impairs
one's ability to correctly respond to facial affect. The present
study was unable to investigate this hypothesis as it was a
self-paced task. Future studies should employ a dynamic face
processing paradigm to determine if this indeed is the case.
We found that CBD alone can reverse the impairment in
faces that are slightly more unambiguous supporting its
potential role in the treatment of disorders characterised by
impairments in emotional facial affect processing. A recent
proposal suggesting that the mood effects of psychotropic
drugs are mediated through processing of emotional informa-
tion in the absence of effects on subjective states (Harmer
et al., 2009) might explain why a single dose of CBD improved
emotional affect recognition in the absence of any effects on
mood (VAS ‘anxiety’). It remains to be established whether
drugs such as CBD might be effective in alleviating emotional
processing deﬁcits after repeated dosing.
In smoked cannabis, the relative active THC/CBD combi-
nation suggests CBD is antagonistic to the psychological and
memory impairing effect of THC (Morgan et al., 2010b,
2012; Morgan and Curran, 2008). It is also difﬁcult to
identify when the effect of CBD will potentiate or antag-
onise the effects of THC as there is little evidence about the
interaction of these two cannabinoids in humans, especially
on cognition and mood. Our exploratory analysis comparing
THC alone with THC combined with CBD suggests that when
given this combination, participants performed better at
40% then THC alone. Further, we did not ﬁnd an effect of
inhaled THC+CBD compared to placebo. Thus, at this
intensity, both conditions performed equally such that CBD
seems to normalise emotional processing when combined
with THC. Moreover, a combination of THC and CBD
produced subjective effects equal to THC alone, replicating
our previous ﬁnding in smoked cannabis that CBD does not
reduce the feeling of ‘stoned’ (Morgan et al., 2010a).
Participants were chosen for high and low frequency of use
(Platt et al., 2010; Hindocha et al., 2014) and schizotypy
(Morgan et al., 2012); as it was hypothesised that cannabi-
noids would differentially act on emotional facial affect
recognition in groups with varying vulnerabilities to cannabis
use. Contrary to this hypothesis, we found no interaction
with frequency of use or schizotypy; THC was equally
detrimental to emotional recognition in heavy and light
cannabis users, with high and low levels of schizotypy. These
ﬁndings correspond with our previous study (Hindocha et al.,
2014) which found that heavy cannabis users show impair-
ment in emotional recognition in comparison to controls,
independent of schizotypy. The equivalent performance of
light and heavy users suggests the chronic effects of canna-
binoids on emotional processing in cannabis users are not
dose-dependent but instead may be a feature of cannabis use
generally. Future research should employ a prospective
design to discern whether these effects are a consequence
of cannabis use or pre-dates cannabis use itself. Importantly,
CBD was equally effective in this wide variety of cannabis
C. Hindocha et al.332users. If CBD were found to have clinical efﬁcacy for emotion
processing deﬁcits, these ﬁndings tentatively suggest that its
beneﬁcial effects would not be compromised in people with
varied heaviness of cannabis use or schizotypy.
The effect sizes of our ﬁndings were in the modest range
(partial eta squared: 0.1–0.3). Bourke et al., (2012) report,
using a similar task, that those with a Major Depressive
Episode (42.2%70.9) or Social Anxiety Disorder (42.6%71.3)
are equally accurate in comparison to healthy controls (42.0%
71.0). Further, they found no interaction between group and
emotion for accuracy, and the effects of intensity were
similar across the groups. Kohler et al. (2003) found that
for mild-intensity faces, healthy controls only perform 4%
better than patients with schizophrenia (61.1% vs. 57.1%). In
comparison, we report here, at 60% emotional intensity,
participants performed 3.6% better on CBD than placebo.
Moreover, at 40%, when given THC, participants perform at
5.2% poorer than placebo. This suggests the effects of single
dose cannabinoid administration are small, but of similar
magnitude to that of clinical populations in previous research
(e.g., Kohler et al., 2003). Future research is necessary to
determine whether these early experimental results might
lead to adequate beneﬁt in patients, either using single or
repeated doses of cannabinoids.
This study has several strengths; it used a large sample size
in a four-way cross-over and highly controlled laboratory
settings. The Volcano Vaporiser method of administering
cannabinoids produces similar plasma and pulmonal THC
levels in comparison to smoked cannabis cigarettes (Abrams
et al., 2007) and delivers between 34% and 69% of the loaded
THC (Hazekamp et al., 2006). Our ﬁndings of impaired
recognition across all emotions are similar to previous data
comparing cannabis users to controls (Hindocha et al., 2014,
Platt et al., 2010). On the other hand, they differ from
previous studies in which drug effects have emerged for
speciﬁc emotions (e.g. Ballard et al., 2012; Bossong et al.,
2013). Although poor recognition of negative and positive
emotion has been reported elsewhere (for example Major
Depression; Bourke et al., 2010), an alternative explanation
for our ﬁndings is a non-speciﬁc perceptual or attentional
effect independent of emotional processing. Future research
should therefore employ additional tasks in order to address
this issue. An important limitation to note is the lack of THC
and CBD plasma measures, which hinders the ability to make
conclusions about the THC+CBD group, especially as this is
the ﬁrst human study to assess this combination of cannabi-
noids on emotional processing. The plasma levels of THC in
this study would be equivalent to that of Bossong et al.
(2009) which also used 8 mg inhaled THC. Pharmacokinetic/
Pharmacodynamic (PK/PD) models (Strougo et al., 2008)
were applied to this concentration/time proﬁle of THC in
the study by Bossong et al. (2009) and found that 84.5–95.9%
of the maximum CNS effects were still present 45–85 min
after drug administration. This timescale matches the cur-
rent study. Further effects of ‘feelings of stoned’ were still
reported 120 min after drug administration and were still
signiﬁcant in comparison to placebo. This suggests that CNS
effects may be responsible for our current ﬁndings. This
study found no systematic differences in individuals with
high/low frequency of use or schizotypy, there is no reason to
assume that these users are not comparable in levels of
plasma (or CNS) THC and/or CBD. There were also somechanges in ‘trait’ schizotypy and frequency of cannabis use
between when participants were recruited and when they
were tested for this experiment, therefore we caution read-
ers about making interpretations about the lack of between
group effects, which are evident and convincing elsewhere
(D'Souza et al., 2008). When we correlated our key ﬁndings
with the total schizotypy scores and frequency of use, no
correlations emerged which supports the lack of between
group effects. Moreover, urine screens were not conducted,
so we have limited knowledge about the extent of cannabis
and other drug use in between sessions. Future research
should attempt to control for this. Participants were texted
24 h before each testing session, reminding them to remain
abstinent. They also gave self-reported abstinence of canna-
bis, alcohol and other drugs for 24 h before testing sessions.
If residual effects of drugs were an explanation for this
pattern of ﬁndings then we would have expected to ﬁnd
systematic ‘frequency of use effects’ across our data,
because of recent use in heavy users. Finally, our use of a
static version of the face morphing paradigm which may have
less ecological face validity than a dynamic face morphing
paradigm (Platt et al., 2010).
To our knowledge, this is the ﬁrst research to show that
CBD can improve emotional facial affect processing. Never-
theless, it is important to consider these ﬁndings as pre-
liminary. This study used an experimental medicine approach
to investigate predictors of vulnerability, with relatively
small numbers in each sub-group and a large number of
comparisons. Replication of these ﬁndings is warranted
before their clinical relevance can be fully determined. This
study may further be extended by using a range of CBD doses.
A potentially fruitful avenue for investigation may be to
investigate whether CBD can ameliorate emotional proces-
sing deﬁcits that are characteristic of mood disorders such as
depression or anxiety, and furthermore, whether CBD might
be used as an adjunct to psychological and pharmacological
therapies for mood disorders.
4.1. Conclusion
In summary, the ﬁndings of this study add to previous
evidence that acute THC administration reduces cannabis
users' ability to accurately identify facial emotions. Impor-
tantly, this study provides the ﬁrst behavioural evidence
that CBD subtly enhances emotional facial affect recogni-
tion and protects against the impairments produced by THC.
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